2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
08 2021
Historique:
received: 12 03 2021
accepted: 16 03 2021
pubmed: 31 3 2021
medline: 21 12 2021
entrez: 30 3 2021
Statut: ppublish

Résumé

The 2021 guidelines primary panel selected clinically relevant questions and produced updated recommendations, on the basis of important new findings that have emerged since the 2016 guidelines. In patients with clinical atherosclerosis, abdominal aortic aneurysm, most patients with diabetes or chronic kidney disease, and those with low-density lipoprotein cholesterol ≥ 5 mmol/L, statin therapy continues to be recommended. We have introduced the concept of lipid/lipoprotein treatment thresholds for intensifying lipid-lowering therapy with nonstatin agents, and have identified the secondary prevention patients who have been shown to derive the largest benefit from intensification of therapy with these agents. For all other patients, we emphasize risk assessment linked to lipid/lipoprotein evaluation to optimize clinical decision-making. Lipoprotein(a) measurement is now recommended once in a patient's lifetime, as part of initial lipid screening to assess cardiovascular risk. For any patient with triglycerides ˃ 1.5 mmol/L, either non-high-density lipoprotein cholesterol or apolipoprotein B are the preferred lipid parameter for screening, rather than low-density lipoprotein cholesterol. We provide updated recommendations regarding the role of coronary artery calcium scoring as a clinical decision tool to aid the decision to initiate statin therapy. There are new recommendations on the preventative care of women with hypertensive disorders of pregnancy. Health behaviour modification, including regular exercise and a heart-healthy diet, remain the cornerstone of cardiovascular disease prevention. These guidelines are intended to provide a platform for meaningful conversation and shared-decision making between patient and care provider, so that individual decisions can be made for risk screening, assessment, and treatment.

Identifiants

pubmed: 33781847
pii: S0828-282X(21)00165-3
doi: 10.1016/j.cjca.2021.03.016
pii:
doi:

Substances chimiques

Apolipoproteins B 0
Cholesterol, HDL 0
Cholesterol, LDL 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0
PCSK9 Inhibitors 0
eicosapentaenoic acid ethyl ester 6GC8A4PAYH
Eicosapentaenoic Acid AAN7QOV9EA
Ezetimibe EOR26LQQ24

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

1129-1150

Informations de copyright

Copyright © 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Glen J Pearson (GJ)

Faculty of Medicine and Dentistry, University of Alberta, Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada. Electronic address: Glen.Pearson@ualberta.ca.

George Thanassoulis (G)

McGill University Health Center, McGill University, Montréal, Québec, Canada.

Todd J Anderson (TJ)

Cumming School of Medicine, University of Calgary, Libin Cardiovascular Institute, Calgary, Alberta, Canada.

Arden R Barry (AR)

University of British Columbia, Vancouver, British Columbia, Canada.

Patrick Couture (P)

Centre Hospitalier Universitaire de Québec, Université Laval, Québec, Québec, Canada.

Natalie Dayan (N)

McGill University, Montréal, Québec, Canada.

Gordon A Francis (GA)

Centre for Heart Lung Innovation, Providence Health Care Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.

Jacques Genest (J)

McGill University Health Center, McGill University, Montréal, Québec, Canada.

Jean Grégoire (J)

Institut de Cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada.

Steven A Grover (SA)

McGill University, Montréal, Québec, Canada.

Milan Gupta (M)

Department of Medicine, McMaster University, Hamilton, Ontario, and Canadian Collaborative Research Network, Brampton, Ontario, Canada.

Robert A Hegele (RA)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

David Lau (D)

Department of Medicine, Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Lawrence A Leiter (LA)

Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

Alexander A Leung (AA)

Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Eva Lonn (E)

Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.

G B John Mancini (GBJ)

University of British Columbia; Department of Medicine, Division of Cardiology, Vancouver, British Columbia, Canada.

Priya Manjoo (P)

University of British Columbia, Victoria, British Columbia, Canada.

Ruth McPherson (R)

University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Daniel Ngui (D)

University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada.

Marie-Eve Piché (ME)

Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Québec City, Québec, Canada.

Paul Poirier (P)

Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Québec City, Québec, Canada.

John Sievenpiper (J)

Department of Medicine and Li Ka Shing Knowledge Institute, St Michael's Hospital and Departments of Nutritional Sciences and Medicine, University of Toronto, Toronto, Ontario, Canada.

James Stone (J)

University of Calgary, Libin Cardiovascular Institute, Calgary, Alberta, Canada.

Rick Ward (R)

Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Wendy Wray (W)

McGill University Health Centre, Montréal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH